Published on
December 6, 2016
- 12:00 GMT
Pluristem’s PLX-R18 Advances into Second Cohort of Dose Selection Study for Treatment of Acute Radiation Syndrome
NIH’s NIAID completes first cohort of dose selection study Data from completed study expected in first half of 2017 Upon determining the optimal dose, a pivotal trial could be conducted to support marketing authorization of PLX-R18 for ARS under the FDA …
Distribution channels:
Technology
